title: [Solid malignancy in patients who received cyclosporine for fibrosing interstitial pneumonia].
abstract: OBJECTIVE
  Since more solid malignancies are observed in transplant recipients treated with cyclosporine (CsA) than in healthy persons. We sought to describe the incidence of malignancy in patients treated with CsA for fibrosing interstitial pneumonia.
  
  
  METHODS
  We prospectively reviewed 43 patients who received CsA and prednisolone for fibrosing interstitial pneumonia over 180 days at our hospital between April 2004 and October 2008. The duration of CsA treatment was 632 +/- 364 days.
  
  
  RESULTS
  Malignancy developed in 6 (14.0%) patients. Time to diagnosis after medical intervention ranged from 394 days to 1325 days (mean, 783 days). Non-small cell lung cancer was diagnosed in 4 cases. These were discovered by routine computed tomography in all cases. Hepatocellular carcinoma and gastric cancer were each diagnosed in 1 case, respectively. Incidence of malignancy tended to be higher in patients who had been treated with CsA for 567 days or more than in those who had been treated for less than 567 days, but this was not statistically significant.
  
  
  CONCLUSIONS
  Our results highlight the need for close follow-up for patients who receive CsA for over 2 years. This could lead to cancer detection at an early stage.
authors.affiliation: Division of Respiratory Medicine, Saiseikai Kumamoto Hospital.
authors.forename: Kodai
authors.initials: K
authors.lastname: Kawamura
authors.forename: Kazuya
authors.initials: K
authors.lastname: Ichikado
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Muranaka
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Gushima
authors.forename: Norihiro
authors.initials: N
authors.lastname: Iwamoto
authors.forename: Makoto
authors.initials: M
authors.lastname: Takaki
authors.forename: Tomoya
authors.initials: T
authors.lastname: Kuda
authors.forename: Mitsuko
authors.initials: M
authors.lastname: Honda
authors.forename: Naoko
authors.initials: N
authors.lastname: Arakawa
authors.forename: Moritaka
authors.initials: M
authors.lastname: Suga
mesh_terms: D000368:Aged; D065095:Calcineurin Inhibitors; D015331:Cohort Studies; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000737:chemistry*; D011446:Prospective Studies; D013256:Steroids / Q000008:administration & dosage
chemical_list: D065095:Calcineurin Inhibitors; D013256:Steroids; D016572:Cyclosporine